Know Cancer

or
forgot password

Ceprotin Treatment Registry


N/A
N/A
N/A
Open (Enrolling)
Both
Severe Congenital Protein C Deficiency

Thank you

Trial Information

Ceprotin Treatment Registry


Inclusion Criteria:



Subjects for whom CEPROTIN therapy has been indicated and meeting the following criteria
may be enrolled in this study:

- Signed and dated informed consent from either the subject or the subject's legally
authorized representative prior to enrollment, as applicable

- Males and females of any age, including neonates, children, adolescents and adults

- Subject who received CEPROTIN or is initiating/receiving CEPROTIN treatment

Exclusion Criteria:

- None

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Medical diagnoses associated with Ceprotin treatment

Outcome Time Frame:

June 2015

Safety Issue:

No

Principal Investigator

Neil Inhaber, MD

Investigator Role:

Study Director

Investigator Affiliation:

Baxter Healthcare Corporation

Authority:

United States: Food and Drug Administration

Study ID:

400701

NCT ID:

NCT01127529

Start Date:

June 2010

Completion Date:

September 2015

Related Keywords:

  • Severe Congenital Protein C Deficiency
  • Protein C Deficiency

Name

Location

Dartmouth-Hitchcock Medical CenterLebanon, New Hampshire  03756
PHS Phoenix Children´s HospitalPhoenix, Arizona  85016
Choc Children´s HospitalOrange, California  92868
Colorado Hemophilia and Thrombosis Center (University of Colorado Denver)Aurora, Colorado  80045
Indiana Hemophilia & Thrombosis Center, Inc.Indianapolis, Indiana  46260
Children´s Hospital BostonBoston, Massachusetts  02115
Spectrum Health Helen Devos Children´s HospitalGrand Rapids, Michigan  49503
Cancer and Blood Diseases InstituteCincinnati, Ohio  45229
Nationwide Children´s HospitalColumbus, Ohio  43205
The Children´s Medical Center of DaytonDayton, Ohio  45404-1815
Cook Children´s Home HealthFt. Worth, Texas  76104
Texas Children´s HospitalHouston, Texas  77030